Retatrutide Dosing Protocol & Titration Schedule: 1mg to 12mg Weekly Guide (2026)

## Quick Reference: Retatrutide Titration Schedule | Week | Dose | Frequency | Expected Outcome | |------|------|-----------|------------------| | 1–4 | 1mg | Once weekly | GI adaptation, minimal weight change | | 5–8 | 2mg | Once weekly | Appetite reduction begins | | 9–12 | 4mg | Once weekly | Therapeutic effect (~17% weight loss) | | 13–16 | 8mg | Once weekly | Enhanced effect (~22% weight loss) | | 17–20 | 12mg | Once weekly | Maximum effect (~24% weight loss) | *Most patients do not need to reach 12mg. Many achieve excellent results at 4mg or 8mg.* --- ## You have the vial in your hands. Now what? Getting retatrutide dosing right is not just about following a chart -- it is the single biggest factor in whether you tolerate the medication well enough to stay on it long-term. In the Phase 2 trial (Jastreboff et al., NEJM 2023), participants who followed the structured titration from 1mg to their target dose reported manageable side effects at rates comparable to other incretin therapies. The patients who struggle are almost always those who escalated too quickly. This guide walks through every dose phase, explains the math behind compounded vial calculations, and shares practical strategies we have gathered from clinical experience. For side effect management at each dose, see our companion [retatrutide side effects guide](/guides/retatrutide-side-effects-management-guide). Updated March 2026. ## The Clinical Trial Dose Levels The Phase 2 trial studied five dose levels, each with a distinct role: - **1mg** -- Initiation. Lets your body meet the triple-receptor mechanism - **2mg** -- First escalation. GI adaptation continues - **4mg** -- Low therapeutic. ~17% weight loss at 48 weeks in trial data - **8mg** -- Medium therapeutic. ~22% weight loss. Where many patients land - **12mg** -- Maximum studied. ~24.2% weight loss. Not everyone needs it ### Why Titration Matters More with Retatrutide Retatrutide is not just a stronger GLP-1. The glucagon receptor adds metabolic effects (thermogenesis, fat oxidation) that your body needs time to adjust to. Jumping from 1mg to 4mg in two weeks, for example, can trigger nausea and energy swings that a slower ramp avoids entirely. Think of it as introducing three new signals to your metabolism rather than one. ## Phase-by-Phase Titration Protocol ### Phase 1: Initiation -- Weeks 1-4 (1mg Weekly) This dose is deliberately sub-therapeutic. Its purpose is letting your GI tract and metabolic system adjust without overwhelming you. **What to expect:** Minimal weight change (0-2%). Some patients notice subtle appetite shifts -- eating slightly less at dinner, for instance, without realizing why. Roughly 10-15% of people experience mild nausea during the first week; it almost always resolves within days. **What to do during this phase:** - Pick a consistent injection day and time (we recommend the same day each week) - Record your starting weight, waist circumference, and how you feel - Start increasing your water intake to 80+ ounces daily - Begin tracking protein consumption -- you will need 100-150g daily later ### Phase 2: First Escalation -- Weeks 5-8 (2mg Weekly) **What to expect:** Appetite reduction becomes noticeable. Most patients describe eating about 20-30% less without effort. Weight loss typically begins -- 2-5% over this phase. Mild GI effects are possible and usually transient. **Practical strategies:** - Eat protein-first at every meal to preserve lean mass during weight loss - If nausea occurs, try injecting in the evening so the peak effect hits while you sleep - Keep bland foods on hand (crackers, rice, broth) for the first 48 hours after each injection ### Phase 3: Therapeutic Dose -- Weeks 9-16 (4mg Weekly) This is where results become obvious. The trial data showed ~17% weight loss at 48 weeks for participants who stayed at this dose. For many patients, 4mg is enough. **What to expect:** Strong appetite control. Measurable metabolic improvements in bloodwork (fasting glucose, triglycerides). Energy levels typically stabilize or improve. The glucagon-mediated thermogenesis starts contributing meaningfully at this dose. **When to stay here:** If you are losing 1-2 lbs per week consistently, your appetite is well-controlled, and side effects are minimal, there is no rush to escalate. Staying at 4mg long-term is a perfectly valid clinical strategy. ### Phase 4: Enhanced Effect -- Weeks 17-24 (8mg Weekly) **What to expect:** Maximum appetite suppression for most people. Enhanced metabolic rate from glucagon activation becomes more pronounced. Trial participants at this dose averaged ~22% weight loss -- comparable to the highest dose of [tirzepatide](/guides/tirzepatide-vs-semaglutide-comparison) but in fewer weeks. **Key clinical data:** The jump from 4mg to 8mg produced the steepest acceleration in fat loss during the trial. Blood sugar control improved substantially, with A1C reductions of 1.5-2.0% reported. **Watch for:** Slightly elevated resting heart rate (5-10 bpm). This is expected from glucagon activation and usually stabilizes. If sustained above 100 bpm at rest, contact your provider. ### Phase 5: Maximum Dose -- Weeks 25+ (12mg Weekly, if needed) **What to expect:** Peak therapeutic effect. The trial showed 24.2% average weight loss, with over half of participants losing 25%+ body weight. Strong thermogenic effects. **Important:** Not every patient needs 12mg. Many achieve their goals at 4mg or 8mg. Escalate only if weight loss has stalled, appetite suppression is waning, and your provider agrees. Higher doses mean higher cost and potentially more side effects without proportionally better results for everyone. ## Calculating Doses from Compounded Vials ### Standard 10mg/ml Concentration If you [reconstitute a 30mg vial](/guides/how-to-reconstitute-retatrutide-mixing-guide) with 3ml of bacteriostatic water (or 60mg with 6ml): | Desired Dose | Volume | Insulin Syringe Units | |-------------|--------|----------------------| | 1mg | 0.10ml | 10 units | | 2mg | 0.20ml | 20 units | | 4mg | 0.40ml | 40 units | | 8mg | 0.80ml | 80 units | | 12mg | 1.20ml | Split into 2 injections | **Formula:** Dose (mg) / Concentration (mg/ml) = Volume (ml) ### Splitting Larger Doses For any injection volume exceeding 1ml, split it into two sites. For 12mg at 10mg/ml, draw 0.60ml for each injection and use two different sites (e.g., left abdomen and right thigh). You can inject both the same day. ## When to Adjust Your Protocol **Signs you can increase:** Current dose well tolerated for 4+ weeks, weight loss has stalled for 2+ weeks, appetite suppression weakening, provider approves. **Signs to stay put:** Still losing weight steadily, appetite controlled, minor but manageable side effects. **Signs to consider reducing:** Persistent severe nausea beyond 2 weeks at a dose, weight loss exceeding 3 lbs/week consistently, significant fatigue or quality-of-life impact. ## Lifestyle Factors That Maximize Results at Every Dose 1. **Protein:** 100-150g daily. Non-negotiable for preserving muscle during rapid weight loss. Protein shakes count. 2. **Water:** 80-100 ounces daily. Dehydration worsens every GI side effect. 3. **Movement:** 30 minutes daily -- walking counts. Resistance training 2-3x weekly protects lean mass -- see our [muscle loss prevention guide](/guides/glp1-muscle-loss-prevention-semaglutide-tirzepatide-guide) for specific exercises. 4. **Sleep:** 7-9 hours. Poor sleep blunts appetite hormones and makes side effects feel worse. *Medical disclaimer: Retatrutide is investigational and not FDA approved. Dosing information is based on clinical trial protocols and is for educational purposes only. Work with a qualified healthcare provider — [find a clinic near you](/for-clinics) for personalized dosing decisions. For current pricing, see our [retatrutide cost guide](/guides/retatrutide-cost-price-guide-2026), and for how retatrutide compares to alternatives, read our [GLP-1 medications comparison](/guides/glp1-medications-comparison-chart-guide).* --- ## References - [Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972). *New England Journal of Medicine*, 2023. - [Retatrutide Phase 2 Trial: Supplementary Appendix (Dosing Protocol)](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2301972/suppl_file/nejmoa2301972_appendix.pdf). *New England Journal of Medicine*, 2023. - [Pharmacokinetics of Retatrutide (LY3437943) in Healthy Volunteers](https://pubmed.ncbi.nlm.nih.gov/?term=Pharmacokinetics+of+Retatrutide+(LY3437943)+in+Healthy). *Clinical Pharmacology & Therapeutics*, 2023. - [Subcutaneous Injection Technique: Best Practices](https://pubmed.ncbi.nlm.nih.gov/?term=Subcutaneous+Injection+Technique:+Best+Practices). *American Journal of Nursing*, 2022.